Zygomycosis is an important emerging fungal infection, associated with high morbidity and mortality. The Working Group on Zygomycosis of the European and Lichtheimia (formerly Absidia) spp (19%) were most commonly identified.
Introduction
Although often described as a rare fungal infection, zygomycosis (mucormycosis) appears to be increasing in frequency [1] . It mainly affects immunocompromised patients, such as those with haematological malignancies, recipients of hematopoietic stem cell (HSCT) [2] or solid organ transplants (SOT) [3] , patients with diabetes mellitus and ketoacidosis [4, 5] , as well as infants with prematurity [6] . Zygomycosis may also affect immunocompetent patients with trauma, burns or patients with elevated serum levels of iron under treatment with deferroxamine. The increased frequency of this infection is attributed to the rising prevalence of diabetes mellitus as well as to the increased use of immunosuppressive treatments. The introduction of newer antifungals, in particular that of voriconazole, has also been suggested to play a role in the increased incidence of zygomycosis [7] . Due to the relative rarity of the disease it is difficult to perform stringent epidemiological studies to estimate its exact incidence. Most of the available data stem from case series and pertain to hematological patients [8] or to patients who have undergone transplantation [9] .
An active population-based surveillance in the Bay Area of San Francisco, USA, was published in 1998 [10] .
While mortality approached 100% in older literature depending on the patients' underlying disease and the type of zygomycosis [11] , it has been reduced since amphotericin B has become available [12] . Since then, however, it has remained essentially unchanged. Nevertheless, with the availability of the less toxic lipid formulations, survival rates of up to 85% have recently been reported in select patient populations [13, 14] .
Taking into consideration the challenges related to epidemiology, treatment and outcome of zygomycosis, a working group on zygomycosis was formed by 
Patients and Methods

Study design
In each participating European country, a national co-ordinator was appointed who was prospectively collecting zygomycosis cases, recorded by the treating physicians in standardized case report forms (CRFs), which were then sent either by e-mail or fax to the general study co-ordinator. The national coordinators were all experts in the field of zygomycosis and in most cases were appointed by the respective national Mycology Societies. The participating hospitals were selected by the national co-ordinator on the basis of their capacity to document all episodes of zygomycosis occurring during the study period.
Mucorales isolates were initially identified at the participating institutions by the routine methods used in each laboratory. Molecular identification was then performed either at a national center (Institut Pasteur in Paris, Medical University in Innsbruck, etc) or the isolates were sent to a central laboratory in Spain (National Center for Mycology, Madrid) for sequencing. Furthermore, coordinators were informed that they could send paraffin-embedded tissue for PCR identification to a central laboratory in Germany [15] .
In order to be included as case in the registry, sufficient information regarding diagnosis, predisposing factors and clinical presentation had to be provided. The CRFs were reviewed by the principal investigators (GP and AS) and queries were sent to the national co-ordinators in order to complete missing data. After completing the database, a data review committee examined all the dataThe study was approved by the Ethics Committee of the University of Athens "Laikon General Hospital", in Athens, Greece, the institution of the principal investigators In addition, approval was also obtained from local ethics committees of all collaborating countries according to local regulations.
Definitions
For the classification of each case as proven or probable, the revised definitions of invasive fungal disease of the European Organization for Research and Treatment of Cancer/ Mycosis Study Group (EORTC/MSG) were used [16] , with the following modification: if the diagnosis was made by histology and there was PCR testing on tissue positive for zygomycetes (from the central laboratory described above), the case was classified as proven zygomycosis, even if there were no cultures available. In addition, diabetes mellitus was also included in the host criteria.
Diagnosis by histology was made if large, non-septate hyphae were reported.The sites of infection were classified as recently described by Roden et al. [4] . Mortality was assessed as all-cause mortality during the course of zygomycosis.
Statistical analysis
Statistical analyses were conducted using SPSS v. 16 . Differences between the qualitative variables in two or more groups were analyzed by a Chi square -test.
A two-sided P value of <0.05 was considered significant. For the estimation of predictors of outcome the following method was used: Univariate analysis was performed using logistic regression for each variable separately. Variables years, ranging from one month to 87 years; 60% of the patients were of male gender. Seventeen patients were younger than 14 years and three were ≤1 year old.
Underlying conditions
The patients' underlying conditions are listed in In another two patients no predisposing factor was found. Thus, in total, there were 18 (8%) patients that were considered immunocompetent.
The majority of children in the <14 year age group had an underlying hematologic malignancy (n=8, 47%), while the rest had trauma (2), solid organ transplantation (2), allogeneic bone marrow transplantation (1), osteosarcoma
(1), type I diabetes mellitus (1), aplastic anemia (1) and Pearson's syndrome (1).
Two of the 3 infants had undergone solid organ transplantation and one had
Pearson's syndrome.
Sites of infection
The types of infection by site are shown in 
Treatment and outcome
Various approaches to treatment were used, including antifungal chemotherapy and surgery (Table 5) . Of the 230 patients included in the study, data regarding antifungal medication was available for 225 patients. Thirty-three patients received no antifungal medication, either because the diagnosis was made at post-mortem (in 10), or during the last 24 hours prior to death (in 14), or because only surgical treatment was performed (in 9). Zygomycosis was successfully cured by the sole use of surgery in two patients who were burn victims with cutaneous disease, in two patients who had maxillary sinusitis but were otherwise immunocompetent and in one patient who had a brain abscess.
Of the 192 patients who received antifungal medication, 167 (87%) received amphotericin B as first line treatment. The formulation used most frequently was liposomal amphotericin B (130/167 patients, 78%). In 10 (6%) cases the formulation of amphotericin B used was unspecified, in 21 (13%) it was amphotericin B deoxycholate and in 7 (4%) it was amphotericin B lipid complex.
Amphotericin B was given either alone or in combination with other antifungal agents ( Table 6 ). In some cases where administration of amphotericin B was followed by posaconazole, there were reports of lengths of treatment of as long as 603 days. In the group of patients who received liposomal amphotericin B as the only antifungal medication and were cured, the median duration of treatment was 55 days (range, 14 to 169 days) and the median daily dose was 5 mg/kg (range, 3 to 10 mg/kg).
Total mortality was 47%. Mortality in the children's group was 27%.
Mortality rates were variable depending on the underlying diseases (Table 1) , on the site of infection (Table 2) , as well as on treatment (Tables 5, 6 ). Table 7 shows the risk factors affecting mortality found to be significant on univariate and multivariate analysis, respectively. As shown on multivariate analysis,age was an independent predictor of death. Increase of age by one year augments the risk of death by 3%. The same statistical model showed that patients who developed zygomycosis as a result of trauma had an 86% smaller probability of death compared to patients with hematological malignancies. Amphotericin B, either alone or with posaconazole or with posaconazole and other antifungals (in combination or sequentially) significantly decreased the risk of death. Finally, surgical treatment decreased the risk of death by 79%. Regarding administration of antifungals prior to the diagnosis of zygomycosis, voriconazole and caspofungin were found to be risk factors on univariate analysis, but only caspofungin remained as an independent risk factor on multivariate analysis.
Discussion
Thus far, this is the largest and geographically most diverse study on the contemporary epidemiology of zygomycosis in Europe. While no conclusions regarding incidence rates are feasible due to the absence of a denominator, however, several important observations can be made that are helpful to better understand the current evolution of the disease. The most common underlying diseases were hematological malignancies (n=102, 44%), while diabetes was found in 39 patients (17%). This is in contrast to the extensive literature compilation by Roden et al. who reported that malignancies constituted 17% of all cases, whereas diabetes was the underlying condition in 36% of 929 cases [4] . This could be explained by the fact that the number of immunocompromised patients has dramatically increased in recent decades. It may also be partly due to the predominance of hematology centers participating in the study. In the analysis of 41 cases by Ruping et al., malignancies were the predisposing factor in 63% of cases and diabetes in 17%, but in that study also the majority of contributing investigators were hematologists [17] . It is not surprising that incidence rates are different in each study, since there has been no defined denominator in any of them, including the present one. Trauma was found to be a predisposing factor in 17% of cases. Of note, eight of the 18 cases (44%) with surgical trauma were submitted from the same center and constituted an outbreak of zygomycosis in a Greek hospital [18] , significantly thus influencing the percentage
The most common sites of infection were the lungs, the sinuses and the soft tissues. Pulmonary zygomycosis was most common in patients with hematological malignancies and rhinocerebral disease in patients with diabetes ( Fig. 1 ). These associations have been reported in other studies [4, 17, 19] and various pathogenetic mechanisms have been proposed [4] . However, the exact pathogenesis leading to the association between diabetes and rhinocerebral disease is not clear [20] .
The diagnosis of zygomycosis is difficult, despite the availability of modern methods. As a result, 4% of all cases were diagnosed post-mortem (by histology and culture), while another 6% were diagnosed during the last 24 hours before death. Of note, in older series, rates of post-mortem diagnosis were much higher. Administration of voriconazole before the diagnosis of zygomycosis was found to be a risk factor for zygomycosis only on univariate, but not on multivariate analysis. There have been several reports suggesting that voriconazole use may play a role in the increased occurrence of zygomycosis [7, 24] . It has also been postulated that exposure to voriconazole may lead to increased virulence of zygomycetes organisms [25] . Previous treatment with caspofungin was shown to be related to an adverse outcome on multivariate analysis. However, the confidence interval was very large, thus weakening the relevance of this observation. A possible explanation for the relatively poor outcome of patients receiving this antifungal prior to the diagnosis of zygomycosis is that caspofungin was given empirically for a presumed fungal infection, delaying thus the initiation of a drug with potent in vitro activity against zygomycetes (amphotericin B).
A significant number of patients developed breakthrough zygomycosis while receiving prophylactic therapy with an azole (40 fluconazole, 7 itraconazole or 2 posaconazole). In vitro studies have shown that fluconazole has no activity against the Mucorales. Itraconazole may be active against some species [26, 27, 28] , while posaconazole demonstrates good in vitro activity against several zygomycetes [28, 29] , whereas in vivo activity in animal models is species dependent [30] Breakthrough zygomycosis while on prophylaxis with these drugs has been reported in other studies [16, 31, 32] . These observations may signify resistance of some species against these antifungals; another factor that must be taken into account is that both itraconazole and posaconazole have problematic pharmacokinetics and even if the administered dose is correct, the serum levels may be suboptimal and therefore ineffective.
Total mortality in the present study was 47%, which is higher than the one reported in two recent series [17, 21] . Comparing the various clinical presentations, patients with disseminated disease had the highest mortality, followed by patients with pulmonary disease. The best outcome was seen in patients who were immunocompetent, of which only one of 18 died (6%). The underlying disease leading to the worst prognosis was hematopoietic cell transplantation (mortality 76%), while patients with hematologic malignancies and diabetes mellitus had similar outcomes (mortality 52% and 55% respectively). In patients, however, who had only diabetes as an underlying disease, without any additional conditions such as malignancies or trauma (Table 1) , mortality was 44% (8/18).
In conclusion, this large European study found that zygomycosis continues to be a disease with a dismal prognosis in about half of the cases.
Clinicians treating patients with diabetes, hematological malignancies or trauma, or patients who are immunosuppressed for any reason, should have a high index of suspicion for the disease and make every effort to obtain tissue for histology, culture and, if possible, PCR. Combination of liposomal amphotericin B with surgery offers the best chance for recovery.
MEMBERS OF THE ECMMM WORKING GROUP ON ZYGOMYCOSIS
The following investigators (listed by country) also participated in this study. Table 1 . Underlying conditions predisposing to zygomycosis and mortality* * Nineteen patients (8%) had more than one underlying disease, so the total is more than 100%. **The number of patients is smaller in this column than the number in the left column, because some data regarding outcome were missing.
***The patients who underwent transplantation are not included in this group. **** Hematopoietic stem cell transplantations (n=21) were allogeneic, except for two cases, for whom the treating physicians stated that the patients had undergone "bone marrow transplantation" without further clarification. Other***** 9 (4) 4/9 (44) *****One patient had neutropenia due to treatment for psoriatic arthritis, one was receiving deferroxamine, and the other seven were receiving corticosteroids for various reasons (two for chronic obstructive pulmonary disease, two for
Underlying condition
Wegener's granulomatosis, one for panarteritis nodosa, one for Goodpasture's syndrome and one for rheumatoid arthritis) ****The total number of cases for each site is smaller than the one on the second column, because data about outcome was missing in some cases and was not included.
# Sino-orbital refers to cases involving the sinus and orbit, without extension to the brain ## Lung infection was characterized as localized when it was only in the lung tissue and with deep extension when it extended to adjacent tissues, such as the pleura, the heart, etc.
### Cutaneous infection was characterized as localized when it did not extent to underlying tissues (muscle, bone), in which case it was characterized as having deep extension. 
Isolated fungi Number (%)
Rhizopus species 58 (34)
Not speciated 25
Rhizopus arrhizus (Rhizopus oryzae) 24
Rhizopus microsporus 7
Rhizopus microsporus var. rhizopodiformis
1
Rhizopus pusillus 1
Mucor species 33 (19) Not speciated 31
Mucor circinelloides 2
Rhizomucor pusillus 5
Rhizomucor variabilis 4
Lichtheimia species** 32 (19) Not speciated 5
Lichtheimia corymbifera 27
Cunninghamella species 8
Not speciated 3
Cunninghamella bertholletiae 5
Apophysomyces elegans 2 (1)
Saksenae species 1
Zygomycetes not specified Diabetes (n=21)
